Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a therapeutic intervention trial evaluating the clinical utility of a novel blood-based epigenetic biomarker-genome-wide 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA)-for assessing measurable residual disease (MRD) in patients with newly diagnosed acute myeloid leukemia (AML). The study compares the efficacy of hypomethylating agent (HMA)-based therapy versus intensive induction chemotherapy, using the 5hmC biomarker to guide post-induction treatment decisions. Approximately 112 adult patients will be enrolled and assigned to treatment arms based on a stratified sampling scheme. Blood samples will be collected at defined intervals to assess MRD status. Primary endpoints include minimal residual disease (MRD) negativity rate, duration of remission, event-free survival (EFS), and overall survival (OS).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Nowo rozpoznana białaczka ostroszpikowa
- •Oczekiwana długość życia co najmniej 6 miesięcy
- •Chęć i zdolność udziału w badaniu przez cały okres trwania
- •Kobiety mogą uczestniczyć po negatywnym teście ciąży
- •Zgoda na stosowanie antykoncepcji podczas badania i przez 6 miesięcy po jego zakończeniu
✗ Disqualifies
- •Uczestnictwo w innym badaniu leków eksperymentalnych w ostatnich 3 tygodniach
- •Poważne schorzenia towarzyszące, które mogą uniemożliwić uczestnictwo
- •Zaburzenia psychiatryczne lub uzależnienia mogące zakłócić współpracę
- •Potwierdzony dodatni test ciąży
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Houston Methodist Neal Cancer Center
Houston, United States
Trial contact
Danielle Sewell
Titilayo Olubajo
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.